Inclusion Criteria:  Male or female infants born at >36 weeks of gestation and who are 3 months of age (≥76 to ≤104 days) at the time of consent (the day of birth is considered day of life 1). Participants whose parent(s)/legal guardian(s) is willing and able to comply with scheduled visits, treatment plan, and other study procedures. Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study. Participants who are available for the duration of the study and whose parent(s)/legal guardian(s) can be contacted by telephone during study participation. Participants whose parent(s)/legal guardian(s) is capable of giving signed informed consent.  Exclusion Criteria:  Previous anaphylactic reaction to any vaccine or vaccine-related component. Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection. History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae. Significant neurological disorder or history of seizure (including simple febrile seizure). Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required). Family history of congenital or hereditary immunodeficiency. Other medical or psychiatric condition, including recent or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Major known congenital malformation or serious chronic disorder. Previous vaccination with any meningococcal vaccine containing groups A, C, W, or Y.